NewAmsterdam Pharma Co N.V. (NAMS)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Netherlands
Exchange: NASDAQ
Market cap: $2.69B
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 4, 2026
Profit #1391 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 4.5% | 5.6% | 5.6% | 4.5% |
Growth #1437 of 1484 companies
Payout #1117 of 1484 companies
Safety #714 of 1484 companies
Price #1437 of 1484 companies
